Table 3.
Association of antihypertensive drugs, BPV status, and mortality
| Low BPV | High BPV | p value | |
|---|---|---|---|
| Antihypertension drug monoteraphy | |||
| Beta Blockers | 25% | 75% | 0.005 |
| CCBs Non DHP | 16.7% | 83.3% | |
| CCBs DHP | 63.6% | 36.4% | |
| ACEi | 13.3% | 86.7% | |
| ARB | 88.9% | 11.1% | |
| Antihypertension drug combination teraphy | |||
| ACEi/ARB + CCB | 61.5% | 38.5% | 0.084 |
| ACEi/ARB + Diuretic | 25% | 75% | |
| ACEi/ARB + BB | 40% | 60% | |
| BB + Diuretic | 25% | 75% | |
| CCBs + Diuretic | 83% | 16,7% | |
| CCB DHP medication | |||
| CCB DHP | 66.7% | 33.3% | 0.004 |
| Other antihypertensive drugs | 33% | 67% | |
| Mortality | |||
| Death | 71.7% | 28.3% | 0.000 |
| Survive | 28.3% | 41.7% | |
ACEis angiotensin converting enzyme inhibitors, ARBs angiotensin receptor blockers, CCBs calcium channel blockers, DHP Dihidropyridin